|
||
Report |
Correspondence to: Makoto Nakanishi, Department of Biochemistry, Nagoya City University Medical School, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Tel:+81-52-853-8145 Fax:+81-52-842-3955 E-mail:mkt-naka{at}med.nagoya-cu.ac.jp.
Androgens play an important role in the growth of prostate cancer, but the molecular mechanism that underlies development of resistance to antiandrogen therapy remains unknown. Cyclin E has now been shown to increase the transactivation activity of the human androgen receptor (AR) in the presence of its ligand dihydrotestosterone. The enhancement of AR activity by cyclin E was resistant to inhibition by the antiandrogen 5-hydroxyflutamide. Cyclin E was shown to bind directly to the COOH terminus portion of the AB domain of the AR, and to enhance its AF-1 transactivation function. These results suggest that cyclin E functions as a coactivator of the AR, and that aberrant expression of cyclin E in tumors may contribute to persistent activation of AR function, even during androgen ablation therapy.
Key Words: cyclin E, androgen receptor, prostate cancer, coactivator, cell cycle
This article has been cited by other articles:
|
|